Highlights from: The 2008 Genitourinary Cancers Symposium February 14-16, 2008 San Francisco, CA

摘要

Sunitinib-Associated Cardiac Toxicity In January 2006 and February 2007, the Food and Drug Administration granted approval for the use of suni-tinib in gastrointestinal stromal tumors (GIST) after imatinib failure/intolerance and advanced renal cell carcinoma (RCC) based on results from randomized phase III and II trials, respectively. An update of the prescribing information for sunitinib states that recently released safety data from a phase III trial comparing sunitinib and inter-feron (IFN)-OC as first-line therapy for metastatic RCC revealed that the left ventricular ejection fraction (LVEF) in 21% (n = 375) of patients treated with sunitinib was below the lower limit of normal, and a recently published paper found that 19% of patients treated with sunitinib (n = 75) had > 15% reduction in LVEF. Sunitinib-associated decline in LVEF was reversed upon dose modification or discontinuation of treatment. Upon the observation at the Stanford Cancer Center of an unexpectedly high incidence of symptomatic heart failure, a retrospective analysis of patients treated with sunitinib was undertaken to address the apparent treatment-emergent cardiac toxicity of sunitinib.